Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Actinium Pharmaceuticals Inc ATNM

Healthcare Biotechnology
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A... see more

Recent & Breaking News (NYSEAM:ATNM)

Actinium to Participate in the RBC Capital Markets Global Healthcare Conference

Marketwired February 17, 2015

Principal Investigator Dr. John Pagel to Brief Clinicians From Major Bone Marrow Transplant Centers on Upcoming Pivotal Trial of Iomab-B

Marketwired February 12, 2015

Actinium Announces Closing of Public Offering of Common Stock and Warrants

Marketwired February 11, 2015

Actinium's Chief Medical Officer to Participate in the Next Gen Immunotherapeutics Panel at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum on February 23rd

Marketwired February 9, 2015

Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock

Business Wire February 6, 2015

Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

Marketwired February 5, 2015

Actinium Engages Dr. Roland Turck, Former President, Global Specialty Medicine, Bayer Healthcare as Board Advisor

Marketwired February 4, 2015

Actinium to Present at the 17th Annual BIO CEO & Investor Conference

Marketwired February 3, 2015

Actinium to Participate in the Canaccord Genuity Rare Disease and Biopharma One-on-One Day on February 3rd

Marketwired January 28, 2015

Actinium Submits Pre-IND Meeting Request to the U.S. FDA for its Iomab-B Drug Candidate

Marketwired January 26, 2015

Actinium Submits CMC Meeting Request to FDA for Iomab-B to Support IND Filing and Anticipated Commencement of Phase 3 Trial in Mid-2015

Marketwired January 20, 2015

Actinium Initiates cGMP Manufacturing of Iomab-B for Phase 3 Clinical Trial

Marketwired January 12, 2015

Q&A: Actinium Pharmaceuticals Inc. CEO Eyes Orphan Drug Application for Flagship Drug

Accesswire January 12, 2015

Actinium to Present at Biotech Showcase(TM) 2015

Marketwired January 6, 2015

Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg

GlobeNewswire December 16, 2014

Actinium's Scientific Advisory Board Endorses and Supports the Iomab-B Phase 3 Clinical Trial Development Program

Marketwired December 9, 2014

Experts in Leukemia Treatment Support Ongoing Phase 1/2 Study of Actinium's Actimab-A, a Low Intensity Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Ages 60 and Older

Marketwired December 8, 2014

Actinium Receives Orphan-Drug Designation From FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Marketwired December 1, 2014

Actinium to Present at the LD Micro Conference in Los Angeles December 3rd 2014

Marketwired November 20, 2014

RedChip Issues Research Note on Actinium Pharmaceuticals

GlobeNewswire November 11, 2014